Not all patients carrying BRCA1-deficient breast cancer responded equally well; some patients experienced relevant side effects from PARP inhibitors, including myelosuppression, gastrointestinal toxicity, hypercholesterolemia, fatigue, and teratogenicity [200,201]. Here, PARP1 is linked to breast carcinoma.